Immunoglobulin G1 (pH 2, 0.2 M NaCl), SEC-SAXS data
Data type: SASBDB experimental dataStatus: PublishedCurve type: SEC-SASLast updated: 2025-03-17T16:06:56.010203+01:00
DrugBank ID: DB00072 https://go.drugbank.com/drugs/DB00072. Heavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf).
▼
1. Samples, Components and Experimental Conditions Sample & Experiment
Sample 1 · Immunoglobulin G1 (pH 2, 0.2 M NaCl), SEC-SAXS data
Concentration
— – 10.0
Buffer / pH
100 mM glycine-HCl, 200 mM NaCl / 2.0
Experimental temperature
25.0
Facility / beamline
Photon Factory (PF), High Energy Accelerator Research Organization (KEK) / BL-10C
2. Measurements Reported by SASBDB Reported Results
Metric
Method
Value
Uncertainty
Unit
dmax
P(r)
12.85
—
Å
i0
Guinier
0.0956356
—
1/cm
i0
P(r)
0.09482
—
1/cm
mw
Experimental
131.0
—
kDa
mw
Guinier I(0)
131.0
0.2
kDa
mw
Porod
150.0
—
kDa
porod_volume
Porod
240.0
—
ų
rg
Guinier
4.184
0.169
Å
rg
P(r)
4.17
—
Å
These values are reported by SASBDB; SAXSdb did not recalculate them from the experimental curve.
▼
3. Source Fits and Models Source Fits & Models
This entry has no source fit record.
▶
4. Source File Index Source Files
Category
Path
Download status
Size
curve
sasbdb/entries/54/sasdw54/source/SASDW54.dat
downloaded
15968
full_entry_zip
sasbdb/entries/54/sasdw54/source/SASDW54.zip
downloaded
18193
pddf
sasbdb/entries/54/sasdw54/source/SASDW54.out
downloaded
40087
sascif
sasbdb/entries/54/sasdw54/source/SASDW54.sascif
not_available
—
summary
sasbdb/entries/54/sasdw54/source/summary.json
downloaded
8594
▶
5. Experiment Description and Publication Experiment & Publication
Original Experiment Description
Synchrotron SAXS data from solutions of Immunoglobulin G in 100 mM glycine-HCl, 200 mM NaCl, pH 2 were collected on the BL-10C beam line at the Photon Factory High Energy Accelerator Research Organization (KEK; Tsukuba, Japan) using a Pilatus3 2M detector at a sample-detector distance of 2 m and at a wavelength of λ = 0.15 nm (I(s) vs s, where s = 4πsinθ/λ, and 2θ is the scattering angle). In-line size-exclusion chromatography (SEC) SAS was employed. The SEC parameters were as follows: A 400.00 μl sample at 10 mg/ml was injected at a 0.20 ml/min flow rate onto a GE Superdex 200 Increase 10/300 column at 25°C. 13 successive 20 second frames were collected. The data were normalized to the intensity of the transmitted beam and radially averaged; the scattering of the solvent-blank was subtracted.
Related Publication
Title
<scp>IgG4</scp>
and <scp>IgG1</scp>
undergo common acid‐induced compaction into an alternatively folded state
Authors
Imamura H, Honda S
DOI / PMID
10.1002/1873-3468.70031 / —
▼
6. Complete Source Record Complete Source Record
The following content comes directly from the SASBDB entry. Missing values are shown as “—”; SAXSdb does not infer undeclared units.
DrugBank ID: DB00072
https://go.drugbank.com/drugs/DB00072
Heavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf).
experiment.sample.buffer.name
100 mM glycine-HCl, 200 mM NaCl
experiment.sample.buffer.concentration_unit
null
experiment.sample.buffer.comment
null
experiment.sample.buffer.additive
null
experiment.sample.buffer.concentration
null
experiment.sample.buffer.pka
null
experiment.sample.buffer.ph
2.0
experiment.sample.buffer.deuteration
null
experiment.sample.purity_method
null
experiment.sample.name
Immunoglobulin G1 (pH 2, 0.2 M NaCl), SEC-SAXS data
DrugBank ID: DB00072 https://go.drugbank.com/drugs/DB00072. Heavy chains' C-terminal K residues are deleted for Herceptin (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan), commercially available trastuzumab, according to the information in PMDA (Pharmaceuticals and Medical Devices Agency): Review report regarding the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150, on Jan. 16th 2008 (https://www.pmda.go.jp/drugs/2007/P200700066/45004500_21300AMY00128_A100_2.pdf).
experiment_description
Synchrotron SAXS data from solutions of Immunoglobulin G in 100 mM glycine-HCl, 200 mM NaCl, pH 2 were collected on the BL-10C beam line at the Photon Factory High Energy Accelerator Research Organization (KEK; Tsukuba, Japan) using a Pilatus3 2M detector at a sample-detector distance of 2 m and at a wavelength of λ = 0.15 nm (I(s) vs s, where s = 4πsinθ/λ, and 2θ is the scattering angle). In-line size-exclusion chromatography (SEC) SAS was employed. The SEC parameters were as follows: A 400.00 μl sample at 10 mg/ml was injected at a 0.20 ml/min flow rate onto a GE Superdex 200 Increase 10/300 column at 25°C. 13 successive 20 second frames were collected. The data were normalized to the intensity of the transmitted beam and radially averaged; the scattering of the solvent-blank was subtracted.